Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)

Inclusion Criteria: * Diagnosis of locally advanced breast cancer * T \> 2 cm (any N), or any T and positive node(needle biopsy is required if tumor size is less than 2cm) * Non-metastatic disease confirmed by computerized tomography and bone scan * HER2 positive by IHC (+++) and/or Fish (+) according to international definitions (ASCO 2007) * Normal left ventricular ejection fraction (LVEF) * Indication of preoperative chemotherapy * multifocal tumors acceptable provided that the largest tumor is Her2-positive * ECOG 0-1 Exclusion Criteria: * Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast) * Clinically significant comorbidities such as cardiovascular diseases, COPD, renal or liver impairment, psychiatric disorders * LVEF value below institutional limits of normal range * Detected or suspected distant metastasis * Neutrophils lower than 1,500/µL, platelets lower than 100,000/µL, hemoglobin lower than 10 g/dL, AST higher than 2.5x upper limit of normal (ULN), total bilirubin higher than ULN, alkaline phosphatase more than 1.5x ULN